12 results on '"Fujieda Y"'
Search Results
2. Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry.
- Author
-
Kirino Y, Maeda A, Asano T, Migita K, Hidaka Y, Ida H, Kobayashi D, Oda N, Rokutanda R, Fujieda Y, Atsumi T, Kishida D, Kobayashi H, Shiratsuchi M, Shimizu T, Kawakami A, Tanaka K, Tsuji T, Mishima K, Miyamae T, Hasegawa A, Ikeda K, Watanabe T, Yamaguchi Y, Nishikomori R, Ohara O, and Nakajima H
- Abstract
Objective: We aimed to gather real-world clinical evidence of detailed disease activity, treatments, remission rates, and adverse events (AEs) associated with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome in a prospective study., Methods: Patients in Japan suspected of having VEXAS syndrome were enrolled in a registry study. A novel disease activity measure (VEXASCAF) assessing 11 symptoms associated with VEXAS syndrome was evaluated at enrolment and after 3 months. AEs, survival, CRP levels, and treatments were also recorded at enrolment and 3 months after enrolment. All exons of UBA1 were sequenced using a next-generation sequencer to determine the variant allele frequencies of pathogenic variants in the peripheral blood of all patients., Results: Of the 55 registered patients, 30 patients were confirmed to have pathogenic variants of UBA1. All patients were male, with a median age of 73.5 years. VEXASCAF and CRP levels decreased significantly at 3 months post-enrolment, but the oral prednisolone dose did not change. Only two patients achieved complete remission according to FRENVEX at 3 months after enrolment. During the observation period of 6 months, 28 AEs were observed, including 3 deaths, 4 malignancies from two cases, 2 thromboses, and 13 infections (including 4 mycobacterial infections). Inflammation of the lung and cervical region (i.e. parotid and submandibular gland swelling, tonsillitis, cervical swelling, and pain) were the most common AEs., Conclusions: Patients with VEXAS syndrome required high-dose glucocorticoids to achieve remission, and complications-such as malignancy, thrombosis, and infection-occurred frequently within a short observation period., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
3. An Association between HTRA1 and TGF-β 2 in the Vitreous Humor of Patients with Chorioretinal Vascular Diseases.
- Author
-
Fukushima Y, Takahashi S, Nakamura M, Inoue T, Fujieda Y, Sato T, Noguchi S, Tsujikawa M, Sakaguchi H, and Nishida K
- Abstract
Background : The aim of this paper was to investigate the protein concentrations of high-temperature requirement A 1 (HTRA1) and transforming growth factor-β (TGF-β) in the vitreous humor of patients with chorioretinal vascular diseases. Methods : This study measured protein concentrations of HTRA1, TGF-β1-3, and vascular endothelial growth factor A (hereinafter called VEGF) in the vitreous humor from seven eyes of patients with chorioretinal vascular diseases (age-related macular degeneration, diabetic macular edema, and retinal vein occlusion) and six control eyes (idiopathic epiretinal membrane and macular hole). We analyzed the mutual relationship among the protein levels. Results : The protein levels of HTRA1 and VEGF were significantly increased in the chorioretinal vascular disease group compared with the control group (1.57 ± 0.79 ×10-9 mol/mL vs. 0.68 ± 0.79 ×10-9 mol/mL, p = 0.039; 3447.00 ± 3423.47 pg/mL vs. 35.33 ± 79.01 pg/mL, p = 0.046, respectively). TGF-β2 levels were not significantly different between groups (2222.71 ± 1151.25 pg/mL for the chorioretinal vascular disease group vs. 1918.83 ± 744.01 pg/mL for the control group, p = 0.62). The concentration of HTRA1 was strongly associated with TGF-β2 levels in the vitreous humor, independent of VEGF (r = 0.80, p = 0.0010). Conclusions : We revealed that vitreous HTRA1 was increased in patients with chorioretinal vascular diseases and strongly correlated with TGF-β2.
- Published
- 2024
- Full Text
- View/download PDF
4. Phosphatidylserine-Dependent Anti-prothrombin Antibodies as a Key Predictor for Systemic Lupus Erythematosus in Patients with Primary Antiphospholipid Syndrome: A retrospective longitudinal cohort study.
- Author
-
Wei J, Fujieda Y, Fujita Y, Ogata Y, Hisada R, Kono M, Amengual O, Kato M, and Atsumi T
- Abstract
Objectives: Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder characterized by thrombosis and pregnancy morbidity. Although PAPS is distinct from systemic lupus erythematosus (SLE), the two conditions share clinical features and susceptibility genes. Progression from PAPS to SLE is well-recognized. However, risk factors for this transition are poorly understood. We aimed to identify predictors of progression to SLE in patients with PAPS., Methods: A longitudinal single-center study was conducted at Hokkaido University Hospital from 1990 to 2021. Baseline characteristics including clinical features, laboratory data, aPL profiles were compared between patients who progressed to SLE (SLE group) and those who did not (non-SLE group)., Results: Among 64 patients diagnosed with PAPS at baseline, nine (13.8%) progressed to SLE over a mean follow-up of 9 years (incidence rate, 1.61 per 100 person-years). At the diagnosis of PAPS, the SLE group had a higher prevalence of anti-phosphatidylserine/prothrombin antibodies (aPS/PT) and anti-dsDNA antibodies compared to the non-SLE group. Other clinical findings, autoantibody profiles, and serum complement levels were similar between the two groups. Multivariate Cox analysis showed that IgG aPS/PT was significantly associated with SLE development (Hazard ratio: 10.3, 95% CI: 1.13-92.6, p=0.04)., Conclusion: IgG aPS/PT may be a predictive factor for new-onset SLE in patients with PAPS, suggesting its utility in guiding risk stratification and monitoring strategies for these patients., (© Japan College of Rheumatology 2024. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site–for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
5. The muscle tissue transcriptome of idiopathic inflammatory myopathy reflects the muscle damage process by monocytes and presence of skin lesions.
- Author
-
Izuka S, Umezawa N, Komai T, Sugimori Y, Kimura N, Mizoguchi F, Fujieda Y, Ninagawa K, Iwasaki T, Suzuki K, Takeuchi T, Ohmura K, Mimori T, Atsumi T, Kawakami E, Suzuki A, Kochi Y, Yamamoto K, Yasuda S, Okamura T, Ota M, and Fujio K
- Abstract
Objective: To investigate transcriptomic and immunophenotypic features of muscle specimens from patients with idiopathic inflammatory myopathy (IIM)., Methods: Bulk RNA-sequencing was performed on muscle biopsy samples from 16 patients with dermatomyositis (DM) and 9 patients with polymyositis (PM). Seven tested positive for anti-aminoacyl t-RNA synthetase antibodies in the DM patients (ARS-DM). We conducted weighted gene coexpression network analysis (WGCNA), differentially expressed gene (DEG) analysis, and gene set variation analysis (GSVA) to assess contributions of specific pathways. Cell proportions in muscle specimens were estimated using a deconvolution approach., Results: WGCNA revealed significant positive correlations between serum creatine kinase (CK) levels and gene modules involved in cellular respiration, phagocytosis, and oxidative phosphorylation (OXPHOS). Significant positive correlations were also observed between CK levels and proportions of CD16-positive and -negative monocytes and myeloid dendritic cells. Notably, DM patients demonstrated enrichment of complement and interferon-α and -γ pathway genes compared to those with PM. Furthermore, ARS-DM demonstrated a higher proportion of Th1 cells and DEGs related to OXPHOS. Additionally, serum Krebs von den Lungen-6 levels correlated with gene modules associated with extracellular matrix and transforming growth factor-β signaling pathway., Conclusion: Our study highlights a significant involvement of monocytes in muscle damage and delineates pathological differences among IIM subtypes. DM was characterized by complement, interferon-α and -γ signaling, whilst ARS-DM was associated with OXPHOS. Distinctive gene expression variations in muscle specimens suggest that different pathologic mechanisms underlie muscle damage in each IIM phenotype., (This article is protected by copyright. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. Relation between hydroxychloroquine dose and continuation rate in patients with systemic lupus erythematosus.
- Author
-
Takeyama S, Kono M, Aso K, Kamada K, Tada M, Tarumi M, Kosumi Y, Yoshimura M, Ninagawa K, Hisada R, Fujieda Y, Kato M, Amengual O, and Atsumi T
- Abstract
Objectives: Hydroxychloroquine (HCQ) is recommended at a target dose of 5 mg/kg per actual body weight to reduce the risk of retinopathy in systemic lupus erythematosus (SLE). However, the efficacy of HCQ has been established at doses of 6.5 mg/kg per ideal body weight. This study aimed to clarify the effects of the HCQ dose on the continuation rate in Japanese patients, who generally have a lower body mass index than Western patients., Methods: This retrospective single-centre observational study enrolled patients with SLE on HCQ therapy. Patients were divided into two groups with a dose per actual body weight [the low-dose (<5 mg/kg) group and the high-dose (≥5 mg/kg) group], and continuation rates were compared. The efficacy of 1-year HCQ therapy was assessed in patients without additional immunosuppressive agents and biologics., Results: Of the 231 patients enrolled, 48 (20.8%) discontinued HCQ. The HCQ dose per actual body weight was identified as an independent risk factor for discontinuation. The low-dose group showed a significantly higher 1-year HCQ continuation rate than the high-dose group (83.2% vs. 72.8%, respectively). Both groups showed reductions in glucocorticoid requirement and serological activity after 1-year HCQ therapy., Conclusions: HCQ <5 mg/kg per actual body weight may facilitate greater continuation., (© Japan College of Rheumatology 2024. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site–for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
7. Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome.
- Author
-
Maeda A, Tsuchida N, Uchiyama Y, Horita N, Kobayashi S, Kishimoto M, Kobayashi D, Matsumoto H, Asano T, Migita K, Kato A, Mori I, Morita H, Matsubara A, Marumo Y, Ito Y, Machiyama T, Shirai T, Ishii T, Kishibe M, Yoshida Y, Hirata S, Akao S, Higuchi A, Rokutanda R, Nagahata K, Takahashi H, Katsuo K, Ohtani T, Fujiwara H, Nagano H, Hosokawa T, Ito T, Haji Y, Yamaguchi H, Hagino N, Shimizu T, Koga T, Kawakami A, Kageyama G, Kobayashi H, Aoki A, Mizokami A, Takeuchi Y, Motohashi R, Hagiyama H, Itagane M, Teruya H, Kato T, Miyoshi Y, Kise T, Yokogawa N, Ishida T, Umeda N, Isogai S, Naniwa T, Yamabe T, Uchino K, Kanasugi J, Takami A, Kondo Y, Furuhashi K, Saito K, Ohno S, Kishimoto D, Yamamoto M, Fujita Y, Fujieda Y, Araki S, Tsushima H, Misawa K, Katagiri A, Kobayashi T, Hashimoto K, Sone T, Hidaka Y, Ida H, Nishikomori R, Doi H, Fujimaki K, Akasaka K, Amano M, Matsushima H, Kashino K, Ohnishi H, Miwa Y, Takahashi N, Takase-Minegishi K, Yoshimi R, Kirino Y, Nakajima H, and Matsumoto N
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Gene Frequency, Hereditary Autoinflammatory Diseases genetics, Hereditary Autoinflammatory Diseases diagnosis, Genetic Variation, Ubiquitin-Activating Enzymes genetics
- Abstract
Objectives: To efficiently detect somatic UBA1 variants and establish a clinical scoring system predicting patients with pathogenic variants in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome., Methods: Eighty-nine Japanese patients with clinically suspected VEXAS syndrome were recruited [81 males and 8 females; median age of onset 69.3 years (interquartile range 62.1-77.6)]. Peptide nucleic acid-clamping PCR (PNA-PCR), regular PCR targeting exon 3 clustering UBA1 variants and subsequent Sanger sequencing were conducted for variant screening. Partitioning digital PCR or targeted amplicon deep sequencing was also performed to evaluate the variant allele frequency (VAF). We developed our clinical scoring system to predict UBA1 variant-positive and -negative patients and assessed the diagnostic value of our system using receiver operating characteristics (ROC) curve analysis., Results: Forty patients (44.9%) with reported pathogenic UBA1 variants were identified, including a case having a variant with VAF of 1.7%, using a highly sensitive method. Our clinical scoring system considering age >50 years, cutaneous lesions, lung involvement, chondritis and macrocytic anaemia efficiently predicted patients with UBA1 variants (the area under the curve for the scoring total was 0.908)., Conclusion: Genetic screening with the combination of regular PCR and PNA-PCR detected somatic UBA1 variants with high sensitivity and specificity. Our scoring system could efficiently predict patients with UBA1 variants., (© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
8. The chest CT signs for pulmonary veno-occlusive disease correlate with pulmonary haemodynamics in systemic sclerosis.
- Author
-
Moriya H, Kato M, Hisada R, Ninagawa K, Tada M, Sakiyama K, Yasuda M, Kono M, Fujieda Y, Amengual O, Kikuchi Y, Tsujino I, Sato T, and Atsumi T
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Adult, Hypertension, Pulmonary physiopathology, Hypertension, Pulmonary diagnostic imaging, Hypertension, Pulmonary etiology, Vascular Resistance physiology, Lung diagnostic imaging, Lung physiopathology, Lung blood supply, Pulmonary Wedge Pressure physiology, Echocardiography methods, Scleroderma, Systemic complications, Scleroderma, Systemic physiopathology, Scleroderma, Systemic diagnostic imaging, Pulmonary Veno-Occlusive Disease diagnostic imaging, Pulmonary Veno-Occlusive Disease physiopathology, Tomography, X-Ray Computed methods, Hemodynamics
- Abstract
Objectives: Pulmonary arterial hypertension associated with systemic sclerosis (PAH-SSc) sometimes accompanies pulmonary veno-occlusive disease (PVOD). We aimed to reveal the relationship between clinical signs of PVOD and severity of pulmonary vasculopathy in SSc., Methods: This study included 52 consecutive SSc patients who had pulmonary haemodynamic abnormalities [mean pulmonary arterial pressure (mPAP) >20 mmHg, pulmonary vascular resistance >2 WU or pulmonary artery wedge pressure (PAWP) >15 mmHg]. A chest CT scan was evaluated in all patients. Patients were divided into two groups, the 0-1 group and the 2-3 group, according to the number of chest CT signs for PVOD, including mediastinal lymph node enlargement, thickened interlobular septal wall and ground glass opacity. Pulmonary haemodynamics, echocardiography and MRI-based cardiac function, pulmonary function and serum biomarkers were compared between the two groups., Results: Mediastinal lymph node enlargement, thickened interlobular septal wall and ground glass opacity were observed in 11 (21%), 32 (62%) and 11 (21%) patients, respectively. The 2-3 group (n = 15) had higher mPAP (P = 0.02) but lower diffusing capacity of carbon monoxide (DLCO)/alveolar volume (P = 0.02) compared with the 0-1 group (n = 37). Other parameters, including PAWP, cardiac output, left ventricular ejection fraction, left atrial diameter, forced vital capacity, brain natriuretic peptide and Krebs von den Lunge-6 were not different between the two groups., Conclusions: The CT signs for PVOD had a positive correlation with mPAP but a negative correlation with DLCO in SSc patients, indicating that PAH-SSc may reflect a spectrum of pulmonary vascular disease that ranges from the pulmonary artery to the vein., (© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
9. Itaconate reduces proliferation and migration of fibroblast-like synoviocytes and ameliorates arthritis models.
- Author
-
Tada M, Kudo Y, Kono M, Kanda M, Takeyama S, Sakiyama K, Ishizu H, Shimizu T, Endo T, Hisada R, Fujieda Y, Kato M, Amengual O, Iwasaki N, and Atsumi T
- Subjects
- Animals, Rats, Male, Mice, Mice, Knockout, Cells, Cultured, Mice, Inbred DBA, Citric Acid Cycle drug effects, Synoviocytes drug effects, Synoviocytes metabolism, Cell Movement drug effects, Arthritis, Experimental drug therapy, Arthritis, Experimental metabolism, Arthritis, Experimental pathology, Cell Proliferation drug effects, Succinates pharmacology, Fibroblasts drug effects, Fibroblasts metabolism, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid metabolism
- Abstract
Fibroblast-like synoviocytes (FLS) play critical roles in rheumatoid arthritis (RA). Itaconate (ITA), an endogenous metabolite derived from the tricarboxylic acid (TCA) cycle, has attracted attention because of its anti-inflammatory, antiviral, and antimicrobial effects. This study evaluated the effect of ITA on FLS and its potential to treat RA. ITA significantly decreased FLS proliferation and migration in vitro, as well as mitochondrial oxidative phosphorylation and glycolysis measured by an extracellular flux analyzer. ITA accumulates metabolites including succinate and citrate in the TCA cycle. In rats with type II collagen-induced arthritis (CIA), intra-articular injection of ITA reduced arthritis and bone erosion. Irg1-deficient mice lacking the ability to produce ITA had more severe arthritis than control mice in the collagen antibody-induced arthritis. ITA ameliorated CIA by inhibiting FLS proliferation and migration. Thus, ITA may be a novel therapeutic agent for RA., Competing Interests: Declaration of competing interest M. Kono has received research grants from GlaxoSmithKline, Mitsubishi Tanabe, Astellas, Sanofi, Taisho, Nippon Shinyaku, Taiju Life Social Welfare Foundation, Kowa, Terumo, Kyocera, Chugai, Mochida, Otsuka, Lotte, Hitachi, Takeda, and Yamazaki Baking, outside the submitted work. M. Kato received research grants and speaker's bureau from AbbVie, Janssen, Nippon Shinyaku, Novartis, Astellas, Eli Lilly, outside the submitted work. T. Atsumi has received grants, consulting fee or speakers' bureau from Astellas, Mitsubishi Tanabe, Chugai, Daiichi Sankyo, Pfizer, TEIJIN, Novartis, Sanofi, GlaxoSmithKline, AbbVie, AstraZeneca, Nippon Boehringer Ingelheim, Janssen, Gilead Sciences, Eli Lilly, ONO, Takeda, Alexion, Kyowa Kirin, Amgen, UCB Japan, and Esai, outside the submitted work. The other authors have no competing interests to declare., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
10. Association of high disease activity and serum IL-6 levels with the incidence of inflammatory major organ events in Behçet disease: a prospective registry study.
- Author
-
Hirahara L, Kirino Y, Soejima Y, Iizuka Y, Yoshimi R, Fujieda Y, Atsumi T, Tono T, Kobayashi D, Meguro A, Takeuchi M, Sakamaki K, Takeno M, Mizuki N, and Nakajima H
- Subjects
- Humans, Male, Female, Adult, Prospective Studies, Incidence, Middle Aged, Inflammation blood, Biomarkers blood, Japan epidemiology, Severity of Illness Index, Behcet Syndrome blood, Behcet Syndrome epidemiology, Registries, Interleukin-6 blood
- Abstract
Background: Little is known about the relationship between the disease activity of Behçet disease (BD) and the incidence of inflammatory major organ events., Objectives: In this prospective registry study, we investigated the association between the Behçet Disease Current Activity Form (BDCAF) and incidence of inflammatory major organ events, defined as the inflammation of the ocular, central nervous, intestinal, and vascular systems in BD., Methods: We enrolled participants from Japanese multicenter prospective cohorts. The BDCAF was evaluated annually. BD-related symptoms, including inflammatory major organ events, were monitored. The association between BDCAF and inflammatory major organ events was analyzed by time-to-event analysis. An unsupervised clustering of the participants' BDCAF, therapeutic agents, and multiple serum cytokines was also performed to examine their association with inflammatory major organ events., Results: A total of 260 patients were included. The patients had a median BDCAF score of 2 [Interquartile range, 1-3] at the enrolment and remained disease active at 1- and 2-year follow-ups, indicating residual disease activity in BD. Patients with a BDCAF score of 0 had a longer inflammatory major organ event-free survival at 52 weeks than those with a score of 1 or higher (p=2.2 x 10
-4 ). Clustering analysis revealed that patients who did not achieve remission despite treatment with tumor necrosis factor inhibitors had high serum inflammatory cytokine levels and incidences of inflammatory major organ events. Among the elevated cytokines, IL-6 was associated with inflammatory major organ events., Conclusion: This study suggests that treatment strategies targeting overall disease activity and monitoring residual serum IL-6 may help prevent inflammatory major organ events in BD., Competing Interests: YK has received support from Amgen speaking fees, support for attending meetings and travel, and advisory board, Novartis speaking fees and advisory board, and Nippon Shinyaku grants. Mitsuhiro Takeno has received consulting and speaking fees from Amgen; research grants and speaking fees from AbbVie, Asahi Kasei, Chugai, Eisai, Tanabe-Mitsubishi, and Taisyo; and speaking fees from Astellas, Asympti, Boehringer-Ingelheim, Eli Lily, Jansen Pharma, Nippon Shinyaku, Novartis, Ono Pharmaceuticals, Takeda, UBC Japan, and Viatris. Tatsuya Atsumi has received grants from Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., TEIJIN PHARMA LIMITED., Eisai Co., Ltd., and Eli Lilly Japan K.K. Tetsuya Atsumi has also received consulting fees from Sanofi K.K, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Janssen Pharmaceutical K.K., Gilead Sciences, Inc., Eli Lilly Japan K.K., and ONO PHARMACEUTICAL CO., LTD. TA has also received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co. Ltd., Pfizer Inc., Alexion Inc., Novartis Pharma K.K., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., AbbVie Inc., Nippon Boehringer Ingelheim Co., Ltd., Amgen Inc. UCB Japan Co. Ltd., AstraZeneca plc, and Eisai Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 Hirahara, Kirino, Soejima, Iizuka, Yoshimi, Fujieda, Atsumi, Tono, Kobayashi, Meguro, Takeuchi, Sakamaki, Takeno, Mizuki and Nakajima.)- Published
- 2024
- Full Text
- View/download PDF
11. Accumulation of Technetium-99m Tetrofosmin on Myocardial Perfusion Scintigraphy in a Patient With Immunoglobulin G4-Related Coronary Periarteritis.
- Author
-
Tsuneta S, Suno K, Fujieda Y, Watanabe M, Watanabe S, Hirata K, Nagai T, and Kudo K
- Subjects
- Humans, Male, Arteritis diagnostic imaging, Arteritis diagnosis, Tomography, Emission-Computed, Single-Photon methods, Middle Aged, Immunoglobulin G blood, Coronary Angiography methods, Coronary Vessels diagnostic imaging, Immunoglobulin G4-Related Disease diagnosis, Immunoglobulin G4-Related Disease complications, Coronary Artery Disease diagnosis, Coronary Artery Disease immunology, Organotechnetium Compounds, Radiopharmaceuticals, Myocardial Perfusion Imaging methods, Organophosphorus Compounds
- Published
- 2024
- Full Text
- View/download PDF
12. Type 1 Cryoglobulinemic Vasculitis Due to Monoclonal Gammopathy of Undetermined Significance Successfully Treated by Bortezomib Plus Dexamethasone.
- Author
-
Kikuchi R, Onozawa M, Nagai J, Okada S, Hasegawa Y, Ohigashi H, Mitamura S, Maeda T, Takakuwa E, Fujieda Y, Goto H, Hashimoto D, Matsuno Y, and Teshima T
- Subjects
- Female, Humans, Middle Aged, Bortezomib therapeutic use, Cryoglobulins, Dexamethasone therapeutic use, Monoclonal Gammopathy of Undetermined Significance complications, Monoclonal Gammopathy of Undetermined Significance drug therapy, Monoclonal Gammopathy of Undetermined Significance diagnosis, Paraproteinemias complications, Cryoglobulinemia complications, Cryoglobulinemia drug therapy, Vasculitis complications, Vasculitis drug therapy
- Abstract
Cryoglobulins are immunoglobulins that precipitate in cold conditions. Type I cryoglobulinemic vasculitis is associated with hematological malignancies. We herein report a case of steroid-resistant type 1 cryoglobulinemic vasculitis associated with monoclonal gammopathy of undetermined significance (MGUS) in a 47-year-old woman. By immunofixation of cryoglobulin, we found that the main component of cryoglobulin was the M protein due to MGUS, so treatment of MGUS was needed. Bortezomib+dexamethasone therapy resulted in a rapid decrease in cryoglobulin and improvement in the symptoms of cryoglobulinemic vasculitis. In refractory type I cryoglobulinemic vasculitis, treatment of the underlying gammaglobulinopathy should be considered.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.